hCAIX/XII-IN-1

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

hCAIX/XII-IN-1 

hCAIX/XII-IN-1 是一种有效的 CAIX/XII 抑制剂，KI 值分别为 0.48 µM 和 0.83 µM。hCAIX/XII-IN-1 显示出体外抗增殖活性。hCAIX/XII-IN-1 诱导 MCF-7 细胞凋亡apoptosis。

hCAIX/XII-IN-1

hCAIX/XII-IN-1 Chemical Structure

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

hCAIX/XII-IN-1 is a potent CAIX/XII inhibitor with the KI values of 0.48 µM and 0.83 µM for CAIX and CAXII, respectively. hCAIX/XII-IN-1 shows antiproliferative activity in vitro. hCAIX/XII-IN-1 induces apoptosis in MCF-7 cells[1].

IC50 & Target

KI: 0.48 µM (CAIX); 0.83 µM (CAXII)[1]
体外研究
(In Vitro)

hCAIX/XII-IN-1 (compound 11a) (3.125, 6.25, 12.5, 25, 50 µM, 48 h) shows antiproliferative activity with an IC50 value of 0.48 µM in MCF-7 cells[1].
hCAIX/XII-IN-1 (0.48 µM; 24 h) increases the cell populations of Sub-G1 phase[1].
hCAIX/XII-IN-1 (0.48 µM) induces apoptosis in MCF-7 cells[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: MCF-7 cells
Concentration: 3.125, 6.25, 12.5, 25, 50 µM
Incubation Time: 48 h
Result: Showed antiproliferative activity with an IC50 value of 0.48 µM in MCF-7 cells.

Cell Cycle Analysis[1]

Cell Line: MCF-7 cells
Concentration: 0.48 µM
Incubation Time: 24 h
Result: Significantly increased the cell populations of Sub-G1 phase.

Apoptosis Analysis[1]

Cell Line: MCF-7 cells
Concentration: 0.48 µM
Incubation Time:
Result: Induced apoptosis in MCF-7 cells.

分子量

397.42

Formula

C19H11NO5S2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Eldehna WM, et al. Discovery of 2,4-thiazolidinedione-tethered coumarins as novel selective inhibitors for carbonic anhydrase IX and XII isoforms. J Enzyme Inhib Med Chem. 2022; 37(1):531-541.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

发表回复